A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Those statements in the following discussion that are not historical in nature should be considered forward-looking statements that are inherently uncertain. Actual results and the timing of the events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the “Cautionary Statement Regarding Forward-Looking Statements” and “Risk Factors” set forth elsewhere in this Annual Report. We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs. In September 2024, the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 491M | 491M | 233M | 145M | - | 227M |
| Net Income | -26M | -26M | -322M | -111M | -278M | -180M |
| EPS | $-0.29 | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 |
| Free Cash Flow | 38M | 38M | -237M | -280M | -186M | -20M |
| ROIC | -14.9% | -6.0% | -87.0% | -19.3% | -66.6% | -34.1% |
| Gross Margin | 97.9% | 97.9% | 96.7% | 92.1% | - | 97.0% |
| Debt/Equity | 2.71 | 2.71 | 7.58 | 1.88 | 8.76 | 0.75 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -63M | -63M | -324M | -388M | -320M | -162M |
| Operating Margin | -12.8% | -12.8% | -138.9% | -267.2% | - | -71.1% |
| ROE | -22.2% | -29.4% | -544.3% | -55.5% | -649.9% | -59.6% |
| Shares Outstanding | 88M | 88M | 79M | 74M | 64M | 60M |
Travere Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 71.6x vs a median of 92.4x. The company's 5-year average gross margin is 95.9%. At current prices, the estimated annualized return to fair value is +4.7%.
Travere Therapeutics, Inc. (TVTX) has a 5-year average return on invested capital (ROIC) of -42.6%. This is below average and may indicate limited pricing power.
Travere Therapeutics, Inc. (TVTX) has a market capitalization of $2.7B. It is classified as a mid-cap stock.
Travere Therapeutics, Inc. (TVTX) does not currently pay a regular dividend.
Travere Therapeutics, Inc. (TVTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Travere Therapeutics, Inc. (TVTX) reported annual revenue of $491 million in its most recent fiscal year, based on SEC EDGAR filings.
Travere Therapeutics, Inc. (TVTX) has a net profit margin of -5.2%. The company is currently unprofitable.
Travere Therapeutics, Inc. (TVTX) generated $38 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Travere Therapeutics, Inc. (TVTX) has a debt-to-equity ratio of 2.71. This indicates higher leverage, which may increase financial risk.
Travere Therapeutics, Inc. (TVTX) reported earnings per share (EPS) of $-0.29 in its most recent fiscal year.
Travere Therapeutics, Inc. (TVTX) has a return on equity (ROE) of -29.4%. A negative ROE may indicate losses or negative equity.
Travere Therapeutics, Inc. (TVTX) has a 5-year average gross margin of 95.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for Travere Therapeutics, Inc. (TVTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Travere Therapeutics, Inc. (TVTX) has a book value per share of $1.30, based on its most recent annual SEC filing.